Psomagen to lead analysis in global genetics study in Parkinson’s
U.S.-based Psomagen, a contract research services provider, has announced that it will lead an analysis of data from the…
Articles by Patricia Inácio, PhD
Presence hallucinations can affect patient’s social perception: Study
When asked to quickly assess the number of people in a room, the average person tends to overcount them. In…
NT-0796 shows sustained easing of inflammation in Phase 1/2 trial
NodThera’s potential oral therapy for Parkinson’s disease, NT-0796, continues to show promise in countering damaging inflammation in treated…
Patient enrollment starts in clinical trial of brain imaging agent
Patient enrollment has started in a Phase 1/2 clinical trial evaluating 18F-OP-801, Ashvattha Therapeutics’ investigational imaging agent…
Targeting reactive astrocytes in brain may lead to novel treatments
Targeting reactive astrocytes — star-shaped cells in the brain that play a supportive role for neurons but can promote…
Combo therapy for inflammation in Parkinson’s may enter clinical trial
A potential anti-inflammatory therapy for Parkinson’s disease may be evaluated in clinical trials within the next year. The investigative…
Parkinson’s patients sought for trial of small intestinal microbiome
An observational clinical trial in Canada that’s investigating the role of the small intestinal microbiome — the population of natural…
Dosing of oral ARV-102 begins in healthy volunteers in Phase 1 trial
A first participant has been dosed in Arvinas’ first-in-human Phase 1 trial testing ARV-102, its oral therapy candidate for neurodegenerative…
Augmented reality can help guide physical therapy for Parkinson’s
Computer scientists at the University of North Carolina at Chapel Hill have developed software and an augmented reality (AR) headset…
Blocking IL-6 release may rescue dopamine-producing nerve cell loss
Suppressing astrocytes’ release of the pro-inflammatory molecule interleukin (IL)-6 reduced the loss of dopaminergic neurons, the nerve cells that are…